Start here if you're new
what it is
Veracyte sells genetic tests that help doctors avoid unnecessary procedures and pick treatments faster.
how it gets paid
Last year Veracyte made $517M in revenue. Decipher urologic tests was the main engine at $190M, or 37% of sales.
why it's growing
FY2025 revenue grew about 16% YoY; Q4 2025 revenue grew about 19% YoY — the old “186% quarter” line was a scrape error.
what just happened
Revenue hit $377M, with EPS at $0.32 and gross margin at 69.2%.
At a glance
B+ balance sheet — decent shape, but not bulletproof
30/100 earnings predictability — expect surprises
Trailing multiple depends on GAAP EPS path (~$1.78 FY2025 in press) — recompute vs. price
2.1% return on capital — nothing to write home about
FY2025 GAAP EPS ~$1.78 (press) — confirm in 10-K
xvary composite: 65/100 — average
What they do
Veracyte sells genetic tests that help doctors avoid unnecessary procedures and pick treatments faster.
Its edge is data and placement. Veracyte says its menu covers 7 of the 10 most common cancers in the U.S., so your doctor can stay in one ecosystem instead of shopping around. The Afirma GRID database includes sequencing across 21,000 genes from more than 200,000 thyroid patients, which makes each new test harder to copy.
How they make money
$517.1M
FY2025 total revenue · +16% YoY (company preliminary/final release)
Decipher urologic tests
$190M
+27.0%
Afirma thyroid tests
$140M
+11.0%
Pulmonary tests
$95M
+16.0%
Breast, colon, bladder and other
$92M
+16.0%
The products that matter
thyroid cancer classifier
Afirma
67,700 tests · +11%
Afirma processed 67,700 tests in 2025, up 11% from the prior year. That steady volume matters because thyroid testing is one of the clearest windows into Veracyte's physician adoption curve.
clinical adoption
prostate cancer classifier
Decipher Prostate
102,000 tests · +27%
Decipher Prostate ran 102,000 tests in 2025, up 27%. That is the fastest volume number on this page, which is why it looks like the growth engine rather than just another product line.
growth engine
breast cancer assay
Prosigna
portfolio support
Prosigna sits inside a portfolio that posted a 70.1% GAAP gross margin in 2025. You do not have clean product-level revenue here, so the read-through is portfolio quality, not segment math.
70.1% margin backdrop
Key numbers
$1.78
FY2025 GAAP EPS
From Veracyte FY2025 press materials (third-party summaries align) — divide price by this for a simple trailing multiple, then compare to adjusted EPS if needed.
2.1%
return on capital
Return on capital → profit earned on the money invested in the business → so what: the company is still weak at turning investment into profit.
~70%
GAAP gross margin
Company cited ~70.1% GAAP gross margin for FY2025 in results materials — round sensibly and confirm in the 10-K tables.
$36M
long-term debt
Long-term debt → money owed beyond one year → so what: debt is just 1% of capital, so the balance sheet is not the problem here.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 1 — safer than 95% of stocks
- price stability 10 / 100
- long-term debt $36M (1% of capital)
B+ — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for VCYT right now.
source: institutional data · return history unavailable
What just happened
filed narrative
Q4 2025: ~$140.6M total revenue (+19% YoY); FY2025 ~$517.1M (+16% YoY).
Q4 GAAP EPS about $0.52 and adjusted EPS about $0.53 in third-party summaries of the release; FY2025 GAAP EPS about $1.78. Testing revenue ~$493M FY2025 in the same materials.
$140.6M
Q4 revenue
$0.52
Q4 GAAP EPS
$517.1M
FY2025 revenue
what changed vs. the old page
We removed the impossible $377M “quarter” and the fake 186% growth rate — those were inconsistent with FY revenue and basic arithmetic.
P0: Veracyte investor release — https://investor.veracyte.com/news-releases/news-release-details/veracyte-announces-preliminary-fourth-quarter-and-full-year-2025
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The #1 risk here is paying a premium multiple for a diagnostics company that still has to hit its 2026 growth guide.
med
valuation wall
VCYT trades at 73.0x trailing earnings while management is guiding for 10–13% revenue growth in 2026. That is a generous setup. If growth merely turns decent, the multiple can do the damage all by itself.
The exposure is simple: a premium multiple on a company with just 12.8% net margin leaves little room for a miss.
med
Candoris ICAV liquidity exposure
A 2025 filing flagged a subscriptions and redemptions account risk tied to Candoris ICAV. The page does not give enough detail to model the exact hit, which is precisely why it belongs in the risk section.
The hard number you do have is $412.9M of cash. That buffer helps, but it does not make opaque exposure disappear.
med
test-volume slowdown
The adoption story is carrying the narrative. Decipher grew 27% and Afirma grew 11% in 2025. If those growth rates cool without a matching jump in pricing or margin, the market loses its favorite reason to pay up.
This matters because the business posted +16.0% revenue growth last year. Slower test growth would hit the core operating story first.
Put the pieces together and you get a clear picture: a safer balance sheet than most stocks, paired with a valuation that assumes clean execution from here.
source: institutional data · regulatory filings · risk analysis
Pay attention to
earnings
next quarterly update
Watch whether management keeps 2026 revenue growth inside the 10–13% range. At 73.0x earnings, reaffirming the range matters almost as much as the quarter itself.
volume
Decipher versus Afirma growth gap
Decipher grew 27% in 2025. Afirma grew 11%. If that gap widens, the product mix story gets more interesting — and more concentrated.
margin
can 27% adjusted EBITDA margin hold
Management beat a 25% target early. The next question is durability. One strong year is progress. Repeating it is the rerating case.
filings
more detail on Candoris ICAV exposure
This is the least transparent risk on the page. Any added disclosure would matter because it helps you separate a footnote issue from a real capital-allocation problem.
Analyst rankings
earnings predictability
30 / 100
Low predictability means the reported numbers can move around more than mature diagnostics peers. In human-speak, do not expect a sleepy quarter-to-quarter story.
risk rank
1
This score says the business itself screens as safer than most stocks. That is balance-sheet safety, not a promise that the share price will behave.
price stability
10 / 100
The stock has been volatile. In plain English: the fundamentals may be improving faster than the market can agree on what they are worth.
source: institutional data
Institutional activity
institutional ownership data for VCYT is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$43
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive